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ABSTRACT
Background: The main difficulty in providing effective
treatment of patients with cancer is distinguishing be-
tween tumor and normal cells. The chimeric molecules
created by cancer-associated chromosomal abnormalities
(such as the BCR-ABL fusion protein) represent ideal
therapeutic targets since they are unique to the disease
state. A major challenge, however, is how to deliver the
specific anti-tumor agent into every tumor cell.
Material and Methods: In this report we describe the
use of a novel strategy to introduce specific anti-tumor
reagents into every tumor cell. It uses retroviral vectors
encoding both antisense transcripts specific for the BCR-
ABLP'90 fusion junction (the specific anti-tumor drug)
and a truncated human CD5 cDNA, which allows selec-
tion of the infected cells. In order to coexpress the anti-
sense molecule with the truncated human CD5 gene, the
picomavirus internal ribosome-entry site was incorpo-
rated in the constructs.
Results: When the antisense transcripts in the CD5-
retroviral vector were introduced into Ba/F3+pl90 cells
rendered interleukin 3 (IL-3) independent by expression
of the BCR-ABL sequences, the cells died upon IL-3
withdrawal, as measured by the absence of CD5-positive
cells. Control Ba/F3+p210 cells infected with the same
virus did not die in the absence of IL-3.
Conclusions: These data suggest a novel strategy for
cancer treatment which incorporates the use of a retro-
virus coexpressing both a selectable surface marker and a
tumor-specific agent.
INTRODUCTION
A key problem in the effective treatment of pa-
tients with cancer (both leukemia and solid tu-
mors) is how to distinguish between tumor and
normal cells. This largely explains why current
cancer treatments are often ineffective. There
have been remarkable advances in our under-
standing of the molecular biology of cancer, pro-
viding new mechanisms for selective tumor de-
struction (1-3). The molecular characterization
of tumor-specific chromosomal abnormalities
has revealed that fusion proteins are involved in
the majority of cancers (4-6). These fusion pro-
teins are encoded by chimaeric genes generated
by the chromosomal rearrangement. These chi-
meric molecules represent ideal therapeutic tar-
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gets since they are unique to the disease state
(they only exist in the tumor cells, not in the
normal cells of the patient) (1-3).
In the hematopoietic system, a well-charac-
terized chromosomal rearrangement brings to-
gether the BCR and ABL genes in Philadelphia
chromosome positive (Phl+) chronic myeloge-
nous leukemia (CML) and acute lymphoblastic
leukemia (Phl+-ALL) cells (7,8-16). Depending
on the precise location of the translocation
breakpoint within the BCR gene, BCR-ABL
fusion proteins of either 210 kD (p210) or 190 kD
(pI90) in size are produced, possessing deregu-
lated ABL tyrosine kinase activity. The p210 and
p190 BCR-ABL oncogenes contain identical
ABL-derived sequences, but differ in the number
of BCR-encoded amino acid residues (8,10,11,
13,17-20). We have previously shown that the
BCR-ABL oncogenes act by inhibiting apoptosis
via a Bcl-2 pathway as a part of their oncogenic
phenotype (21). Inhibition of p190 expression in
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the Ba/F3+pI90 mouse hematopoetic cell line
reverted this phenotype and cells died by apop-
tosis (3,21). This suggested that inhibition of
p190 expression could similarly inhibit the leu-
kemic phenotype of human Phl+ -ALL cells lead-
ing to a new therapeutic approach in this disease.
A major challenge is to deliver an anti-tumor
drug into every tumor cell. If this is not achieved,
any malignant cell that remains unaffected will
emerge as a resistant clone. Several experiments
have demonstrated the feasibility of using anti-
sense oligonucleotides (1,2) to produce se-
quence-specific inhibition of gene expression.
However, these oligonucleotides are unable to
enter the majority of cell types with high effi-
ciency, so that some type of delivery system is
essential (22). In the present study we have em-
ployed a novel strategy to introduce specific anti-
tumor drugs into tumor cells. It uses retroviral
vectors encoding both antisense sequences spe-
cific for the BCR-ABLP'90 fusion junction and a
truncated human CD5 protein encoding only the
extracellular and transmembrane domains and
therefore defective in signal transduction. This
marker allows the selection of all infected cells.
MATERIALS AND METHODS
Plasmid Construction
The MFGA190CD5 and the MFGS190CD5 retro-
viral vectors are based on a simplified MFG ret-
roviral vector, which does not contain a gene for
a dominant selectable marker (23). The sequences
subcloned into the MFG vector (23) were as fol-
lows: 61 nucleotides spanning the BCR-ABL
junction either in antisense (MFGA190CD5 vec-
tor) or sense orientations (MFGS 1 90CD 5 vec-
tor); the picornaviral internal ribosome-entry
site (IRES) sequence (24); and a 1218-bp se-
quence from the human CD5 cDNA encoding
the complete extracytoplasmic region. CD5 DNA
fragments were generated by reverse tran-
scriptase polymerase chain reaction (PCR) using
primers that included initiation and termination
codons. The authenticity of the constructs gen-
erated was confirmed by DNA sequencing and
revealed neither PCR errors nor cloning artifacts.
The proviral structure of these vectors is shown
in Fig. IA below.
Cell Lines
The ecotropic retrovirus packaging cell line 4i-cre
was used to generate helper-free recombinant
retrovirus. The cell line was maintained in Dul-
becco's modified Eagle's medium (DMEM) sup-
plemented with 10% calf serum. Viral packaging
cell lines were maintained in the same medium
supplemented with 1 mg/ml of the neomycin
analog G418 (GIBCO/BRL). The interleukin 3
(IL-3)-independent mouse hematopoietic cell
lines Ba/F3+pl90 and Ba/F3+p210 expressing,
respectively, BCR-ABLP'90 and BCR-ABLP210,
were maintained in DMEM with 10% fetal calf
serum (FCS). When required, 5% of WEHI-3B
conditioned medium was included as a source of
IL-3. All cells were cultured at 370C in a humid-
ified atmosphere of 5% CO2 in air.
Retrovirus Production
4i-cre cells were first transfected with 20 jig of
either MFGA190CD5 or MFGS19OCD5 retroviral
vectors together with 1 ,ug of the pMC lneo vec-
tor by the calcium phosphate precipitation
method. Following G418 selection (1 mg/ml),
clones were selected based on the level of CD5
expression. BCR-ABL-expressing Ba/F3 cells
were infected by 2 days of coculture with the
MFGA190CD5 or the MFGS190CD5 viral pro-
ducer cell lines in DMEM supplemented with
10% calf serum, Polybrene (8 jig/ml), and IL-3.
After coculture, infected cells (as detennined by
CD5 expression) were tested for IL-3 dependence.
Labeling of Cells
Protein production was analyzed by immunoflu-
orescence labeling as follows. Cells were fixed in
4% (w/v) paraformaldehyde for 15 min, washed
in phosphate-buffered saline (PBS), and perme-
abilized in methanol for 2 min. After blocking in
5% FCS in PBS for 30 min, the FITC-directed
conjugated anti-human CD5 monoclonal anti-
body (Pharmingen, San Diego, CA, U.S.A.) was
added and incubated for 30 min. Fluorescent
cells were visualized by epifluorescent micros-
copy. Images were recorded on the confocal
scanning microscope. To sort CD5-positive cells,
MFGS190CD5-infected cells were incubated on
ice for 40 min with the FITC-directed conjugated
anti-human CD5 monoclonal antibody (Pharm-
ingen), washed twice with PBS with 1% FCS and
resuspended in PBS with 1% FCS. Propidium
iodide (Sigma Chemical Co., St. Louis, MO,
U.S.A.) was included in the last wash to distin-
guish dead cells before analysis by flow cytom-
etry using a FACScan cell analyzer (Beckton
Dickinson, Mountain View, CA, U.S.A.). BCR-
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FIG. 1. CD5-recombinant retroviruses encoding BCR-ABLP'90 antisense (MFGA190CD5) and sense
transcripts (MFGS190CD5)
(A) Proviral structure of the vectors. The MFG retroviral vector (23) incorporates 61 nucleotides spanning the
BCR-ABL fusion junction (A) and a 1218-bp sequence of the human CD5 cDNA encoding the complete extracyto-
plasmic region. The vector does not contain a selectable marker. (B) Nucleotide sequence of the BCR-ABL fusion
junction carried by the retroviral vectors in either antisense or sense orientations. (C) Diagrammatic representation
of the human CD5 protein. The portion included in the retroviral vectors is indicated (ShCD5). EX, extracytoplas-
mic domain; TM, transmembrane domain; CY, cytoplasmic domain.
ABL-expressing Ba/F3 cells cultured alone were
used as a negative control. Cells were sorted on a
FACStar+ (Beckton Dickinson) equipped with a
5-W argon and a 30-mW helium neon laser.
Cells were collected in sterile Eppendorf vials in
medium with 50% FCS.
RNA Analysis
Total cytoplasmic RNA (10 ,g) was glyoxylated
and fractioned in 1.4% agarose gels in 10 mM
Na2HPO4 buffer (pH 7.0). After electrophoresis,
the gel was blotted onto Hybond-N (Amersham,
Arlington Heights, IL, U.S.A.), UV-cross-linked,
and hybridized to 32P-labeled probes.
RESULTS
Plasmid Construction
To explore the possible use of coexpressing the
antitumor agent (BCR-ABLP"90 antisense mole-
cules, in this case) and a selectable cell surface
marker (CD5), the retroviral vectors depicted in
Fig. 1 were constructed. These two vectors con-
tained 61 nucleotides long sequences spanning the
BCR-ABLP'90 cDNA fusion junction either in anti-
sense (MFGA190CD5) or sense (MFGS190CD5)
orientations. They also carried a 1218-bp-long
DNA sequence from a portion of the human CD5
cDNA encoding the complete extracytoplasmic
region. The anti-BCR-ABLP'90 sequences and
the truncated human CD5 cDNA would be tran-
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TABLE 1. Viability of CD5+-cells after IL-3
withdrawal
Infected Cells +IL-3 -IL-3
Ba/F3+p190 + MFGA190CD5 6.8% 0%
Ba/F3+p190 + MFGS190CD5 7.2% 7.2%
Ba/F3+p210 + MFGA190CD5 5.9% 5.9%
scribed from promoter/enhancer sequences in
the retroviral long terminal repeat (LTR). In or-
der to coexpress the anti-BCR-ABLP 90 se-
quences with the extracytoplasmic portion from
the human CD5 cDNA, we incorporated in the
vectors the picornaviral internal ribosome-entry
site (IRES). The IRES is a 500-nucleotides-long
sequence which acts as ribosomal binding site
and permits effective internal translation initia-
tion in mammalian cells (24). MFGA190CD5 and
MFGS190CD5 viral producing cells were gener-
ated using the ecotropic qi-cri packaging cell line.
Clones were selected based on high CD5 expres-
sion and had a titer of 0.5 (copy number) as
determined by titering in NIH-3T3 cells.
Specific Inhibition of Ba/F3+pI90 Cells
Infected with MFGA190CD5 Retrovirus
Following IL-3 Withdrawal
Mouse Ba/F3 cells expressing BCR-ABLP'90 (des-
ignated Ba/F3+pl90) were infected with CD5-
retroviruses carrying either sense or antisense
BCR-ABLP'90 junction sequences. The BCR-
ABLP'90 oncogene renders the IL-3-dependent
murine Ba/F3 cell line (25) growth factor inde-
pendent (21,26). In turn, down-regulation of
BCR-ABL oncogene expression restores IL-3 de-
pendence (3,21).
Approximately, 7% of Ba/F3+pl90 cells ex-
pressed high levels of surface CD 5 antigen after 2
days of cocultivation with either MFGA190CD5
or MFGS190CD5 viral producers in the presence
of IL-3 (Table 1 and Fig. 2A, top panels). CD5
expression provided a marker for cells infected
with the retrovirus. Following IL-3 removal, the
Ba/F3+pl9O cells infected with retrovirus carry-
ing antisense BCR-ABLP'90 sequences died, as
determined by lack of CD 5-positive cells (Table 1
and Fig. 2A, bottom left panel). In contrast, Ba/
F3+pl90 cells infected with CD5-retrovirus car-
rying BCR-ABLP'90 sequences in the sense ori-
entation remained viable in the absence of
exogenous IL-3 (Table 1 and Fig. 2A, bottom
right panel). Therefore, the antisense RNA inhib-
ited the function of the BCR-ABLP'90 RNA and
protein.
The specificity of the retrovirally transduced
antisense transcript against BCR-ABLP'90 junc-
tion sequence was tested by infecting Ba/F3 cells
expressing the BCR-ABLp210 fusion protein with
CD5-retrovirus encoding antisense BCR-ABLP'90
junction transcript (Table 1 and Fig. 2B). The
BCR-ABLP'90 and BCR-ABLp210 oncogenes
share 50% homology since the ABL sequences
involved in the gene fusion are the same. How-
ever, the infected BCR-ABLp210-expressing
Ba/F3 cells did not die following IL-3 with-
drawal, indicating that the BCR-ABLP190 anti-
sense sequences are highly specific for BCR-
ABLP190 and not for BCR-ABLP210.
Fluorescence-Activated Cell Sorter
Selection of CD5-Transduced
Ba/F3+p190 Cells
Viable cells infected with the sense BCR-ABLP'90
junction sequences expressed high levels of trun-
cated human CD5, which is not expressed in the
parental mouse cell line, allowing selection of
infected cells by fluorescence-activated cell sort-
ing (FACS) and subsequent propagation of vi-
able CD5-positive cells (Fig. 3). A representa-
tive FACS profile from one experiment shows
that approximately 7% of the Ba/F3+pl90 cells
recovered after infection were positive for the
CD5 cell surface antigen (Fig. 3 B and C). In
three independent experiments, 90-95% of the
Ba/F3+p190 cells recovered in the CD5-positive
fraction were CD5 positive (Fig. 3 D and E) com-
pared with 7% in the unsorted population
(Fig. 3C). Thus, retrovirally transduced Ba/
F3+p190 cells could be successfully enriched
based on their immediate expression of the CD5
gene in vivo. Moreover, as the fraction of CD5-
positive cells did not decrease with extended
propagation, the surface marker does not have
deleterious effects on cell growth and viability.
In order to ensure that the level of BCR-
ABLP190 RNA was indeed reduced in Ba/
F3+pl9O cells following infection with the anti-
sense viral construct, CD 5-positive cells were
selected by FACS sorting in the presence of IL-3
and the level of BCR-ABLP190 mRNA was ana-
lyzed by Northern blot analysis. As illustrated in
Fig. 4, BCR-ABLP'90 RNA levels were signifi-
cantly reduced in selected Ba/F3+pl90 cells in-
fected with the antisense vector. Residual BCR-
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FIG. 2. (A) Specific growth inhibition of Ba/F3+pl90 cells infected with the MFGA190CD5 retrovirus
following IL-3 withdrawal, and (B) The viability of Ba/F3+p210 cells is not affected by MFGA19OCD5
virus
(A) Ba/F3+pl90 cells were infected with recombinant MFGA190CD5 (left panels) or MFGS190CD5 (right panels).
The viability of infected cells was assessed by staining with anti-human CD5 antibody in the absence of IL-3 (bot-
tom panels). (B) Ba/F3+p210 cells were infected with the virus encoding BCR-ABLP'90 antisense transcripts and
the truncated human CD5 surface marker. Infected cells (left panel) were assessed by their viability after IL-3
withdrawal (right panel).
ABLP190 mRNA corresponded to uninfected
CD5-negative cells which were not efficiently
sorted by FACS (data not shown). In contrast,
BCR-ABLP'90 mRNA production was not af-
fected in CD 5-positive selected cells infected with
the sense vector.
The data suggest a possible strategy treating
Philadelphia positive ALL or CML. The strategy
makes use of retrovirus which enables dual ex-
pression of both a selectable marker (truncated
CD5) and a tumor-specific agent (antisense oligo-
nucleotides specific for tumor-associated fusion
proteins). In this way, following ex vivo target-
ing, only cells expressing both a tumor-specific
agent and a selectable cell surface marker would
be used for bone marrow reconstitution in a
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FIG. 3. Selection of CD5 virus-infected Ba/F3+pl90 cells by FACS
The CD5 expression profiles of uninfected Ba/F3+pl90 cells (A and D), Ba/F3+pl90 cells cocultured with CD5
viral producer cells 48 hr postinfection (B), and sorted Ba/F3+pl90 cells (E). (C and F) The immunofluorescence
analysis of Ba/F3+pl90 cells before and after sorting, respectively. Cells were stained with anti-human CD5 anti-
body and analyzed by flow cytometry (A, B, D, and E) and immunofluorescence (C and F).
patient, thus ensuring the highest chance of
eradicating the tumor.
DISCUSSION
Use of Retroviral Vectors to Deliver
Antisense Oligonucleotides in the
BCR-ABL-Expressing Ba/F3 Model
Gene therapy promises to be an effective strategy
for the treatment of cancer. Recombinant retro-
viruses provide an attractive vehicle for gene
transfer because of their capacity for high and
efficient infection, and nontoxic integration into
the genome in a wide range of cell types. We
report a novel strategy to target tumor-associated
fusion proteins using retrovirally transduced an-
tisense sequences targeted against the BCR-ABL
fusion mRNA in Ba/F3+p190 cells. We chose the
Ba/F3+pl90 cell line because it was rendered
IL-3 independent by the expression of p 190-cod-
ing sequences. Following inhibition of p190 ex-
pression by antisense treatment, which causes
cell death in a culture medium deprived of IL-3,
cells can be rescued by addition of exogenous
IL-3. This system is therefore well suited for eval-
uating the efficacy of the technique.
Ba/F3+pl90 cells were infected by a retro-
viral vector carrying selected antisense sequences
designed against the BCR-ABL fusion junction.
The antisense transcripts generated under the
control of the viral promoter specifically killed
Ba/F3+pl90 cells in the absence of IL-3. This
effect was specific since control Ba/F3 +p2lO
cells infected with the same viral constructs did
not die following IL-3 withdrawal. In addition,
the level of BCR-ABLP'90 mRNA was specifically
reduced in selected Ba/F3+p190 cells infected
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FIG. 4. Specific suppression of BCR-ABLP'90
mRNA transcripts in selected Ba/F3+pl90 cells
infected with the antisense virus
Total RNA was isolated from Ba/F3+pl90 cells
(Lane 1), selected Ba/F3+pl90 cells infected with
the antisense virus (Lane 2), and selected Ba/
F3+pI90 cells infected with the sense virus (Lane
3). Cellular RNA was hybridized to a human ABL
probe (top) and to a mouse f3-actin cDNA (bottom).
Autoradiography was for 9 hr at -70°C.
with the antisense virus. We conclude that this
approach successfully achieves suppression of
the oncogenic protein pl90. The effect on fresh
Ph'-ALL cells in bone marrow cultures must be
assessed before this technique may be used to
suppress leukemic hematopoiesis in vitro. While
antisense oligonucleotides are unable to enter
most cell types with high efficiency (22), this
study indicates that retroviral vectors are a suitable
delivery system for antisense oligonucleotides to
produce sequence-specific gene inhibition.
Novel Strategy for Cancer Treatment:
Dual Expression of Both the
Tumor-Specific Agent and the
Selectable Tagging Molecule
Although the efficiency for retrovirus-mediated
gene transfer approaches 100%, this may not be
realized either because of low viral titers or be-
cause of the failure to stimulate cells to divide,
which is required for successful integration.
Moreover, expression of the transferred gene(s)
may not reach the desired levels or be sustained
in cells. Such problems are especially evident in
current efforts to apply the technique to the gene
therapy of cancer; if the anti-tumor vector is not
delivered to every tumor cell, any malignant cell
that is not affected will emerge as a resistant
clone. In this study we have coexpressed the
specific anti-tumor agent (antisense molecules
against the tumor-associated fusion proteins)
with a cDNA encoding a truncated human cell
surface antigen (CD5) which allows immediate
postinfection selection of the hematopoietic cells
transduced with the retrovirus. FACS analysis in
combination with functional studies showed that
under the conditions used, all Ba/F3+pl90 cells
selected expressed CD5 by 48 hr following infec-
tion. Moreover, the fraction of CD5-positive cells
did not decrease with their extended propaga-
tion, indicating that the surface marker does not
have deleterious effects on cell growth and via-
bility. The use of the truncated CD5 cell surface
antigen as a selectable marker of gene transfer
offers significant advantages over other select-
able markers which confer resistance to toxic
compounds. They include rapid and quantitative
detection by flow cytometry of expression of the
transfected genes in the desired target cell pop-
ulation and the efficient and nontoxic selection
of transduced target cells by FACS.
These results suggest a new approach for in
vitro gene therapy of hematopoietic cancer: au-
tografting patients with bone marrow cells in-
fected in vitro with the retrovirus expressing
sequences targeted specifically against the tu-
mor-associated fusion junctions and a selectable
marker, followed by nontoxic selection, ensures
that all reinfused stem cells will contain inte-
grated antisense sequences. This strategy would
thus make it possible to restore cancer-negative
hematopoesis in patients.
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